Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1996 1
1998 1
2000 1
2001 3
2008 2
2010 1
2011 3
2012 1
2013 5
2014 4
2015 8
2016 12
2017 4
2018 8
2019 11
2020 12
2021 7
2022 7
2023 11
2024 6
2025 4
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

98 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean bollenbacher w (56 results)?
Practice variations in indication, timing and outcome of Multiple Myeloma patients undergoing surgery for vertebral lesions - results from the European M2Spine study group.
Hubertus V, Viezens L, Stangenberg M, Früh AM, Meyer HS, Liang R, Kramer A, Orban C, Kerschbaumer J, Kunze B, Telera S, Miller H, Entenmann CJ, von Bronewski EJ, Buhre C, Leonhardt LG, Willenbacher W, Kvitsaridze I, Laue D, Pumberger M, Keller T, Acker G, Krönke J, Blau IW, Keller U, Ringel F, Thomé C, Meyer B, Vajkoczy P, Dreimann M, Onken JS. Hubertus V, et al. Among authors: willenbacher w. J Neurooncol. 2025 Sep;174(3):765-777. doi: 10.1007/s11060-025-05085-y. Epub 2025 Jun 13. J Neurooncol. 2025. PMID: 40512280 Free PMC article.
Real-World Data on the Efficacy of Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma and Amplification 1q.
Benda M, Reimann P, Bletzacher E, Muendlein A, Bernhard B, Hartmann B, Huynh M, Gasser K, Zojer N, Lang T, Göbel G, Bohn JP, Schmidt S, Gunsilius E, Nachbaur D, Jukic E, Locher M, Willenbacher E, Willenbacher W, Winder T, Steiner N. Benda M, et al. Among authors: willenbacher w. Cancers (Basel). 2025 Apr 8;17(8):1261. doi: 10.3390/cancers17081261. Cancers (Basel). 2025. PMID: 40282438 Free PMC article.
Comparing functional and genomic-based precision medicine in blood cancer patients.
Kazianka L, Pichler A, Agreiter C, Rohrbeck J, Kornauth C, Porpaczy E, Sillaber C, Sperr WR, Gleixner KV, Hauswirth A, Jäger U, Valent P, Jonak C, Porkert S, Exner R, Willenbacher W, Wolf D, Neumeister P, Prochazka K, Deutsch A, Greil R, Schmitt C, Ristl R, Mayerhoefer M, Simonitsch-Klupp I, Pemovska T, Staber PB. Kazianka L, et al. Among authors: willenbacher w. Hemasphere. 2025 Apr 24;9(4):e70129. doi: 10.1002/hem3.70129. eCollection 2025 Apr. Hemasphere. 2025. PMID: 40276215 Free PMC article.
Beta-2-Microglobulin Maintains Overall Survival Prediction in Binet A Stage Chronic Lymphocytic Leukemia Patients with Compromised Kidney Function in Both Treatment Eras of Chemoimmunotherapy and Targeted Agents.
Bohn JP, Stolzlechner V, Göbel G, Willenbacher W, Pirklbauer M, Steiner N, Wolf D. Bohn JP, et al. Among authors: willenbacher w. Cancers (Basel). 2024 Nov 6;16(22):3744. doi: 10.3390/cancers16223744. Cancers (Basel). 2024. PMID: 39594701 Free PMC article.
QoL during KTd or KRd induction followed by K maintenance or observation in transplant noneligible patients with newly diagnosed multiple myeloma: Longitudinal and cross-sectional analysis of the randomized AGMT 02 study.
Ludwig H, Melchardt T, Schweitzer I, Sormann S, Schreder M, Andel J, Hartmann B, Zojer N, Schöffmann L, Gunsilius E, Podar K, Egle A, Willenbacher W, Wöll E, Ruckser R, Bozic B, Krauth MT, Petzer A, Schmitt C, Machherndl-Spandl S, Agis H, Fillitz M, Wang SY, Knop S, Greil R. Ludwig H, et al. Among authors: willenbacher w. EJHaem. 2024 May 17;5(3):494-504. doi: 10.1002/jha2.925. eCollection 2024 Jun. EJHaem. 2024. PMID: 38895059 Free PMC article.
Efficacy and safety of tixagevimab/cilgavimab as passive immunisation against COVID-19 infections in patients with hematological malignancies.
Reimann P, Petzer V, Mündlein A, Hartmann B, Severgnini L, Winkler A, Lang T, Huynh M, Gasser K, Rüger J, Atzl M, Mink S, Fraunberger P, Schmidt S, Steiner N, Griesmacher A, Gunsilius E, Nachbaur D, Willenbacher W, Wolf D, Winder T, Benda MA. Reimann P, et al. Among authors: willenbacher w. Ann Hematol. 2024 Jun;103(6):2123-2131. doi: 10.1007/s00277-024-05671-6. Epub 2024 Mar 2. Ann Hematol. 2024. PMID: 38436671
Randomized comparison between KTd and KRd induction therapy followed by maintenance therapy with K or observation in transplant-ineligible patients with newly diagnosed multiple myeloma.
Ludwig H, Melchardt T, Sormann S, Schreder M, Andel J, Hartmann B, Tinchon C, Zojer N, Gunsilius E, Podar K, Egle A, Willenbacher W, Wöll E, Ruckser R, Bozic B, Krauth MT, Petzer A, Schmitt C, Machherndl-Spandl S, Agis H, Fillitz M, Wang SY, Zabernigg A, Knop S, Paiva B, Greil R. Ludwig H, et al. Among authors: willenbacher w. Am J Hematol. 2024 May;99(5):1008-1011. doi: 10.1002/ajh.27280. Epub 2024 Feb 29. Am J Hematol. 2024. PMID: 38425185 Free article. Clinical Trial.
Abnormal biomarkers predict complex FAS or FADD defects missed by exome sequencing.
Rensing-Ehl A, Lorenz MR, Führer M, Willenbacher W, Willenbacher E, Sopper S, Abinun M, Maccari ME, König C, Haegele P, Fuchs S, Castro C, Kury P, Pelle O, Klemann C, Heeg M, Thalhammer J, Wegehaupt O, Fischer M, Goldacker S, Schulte B, Biskup S, Chatelain P, Schuster V, Warnatz K, Grimbacher B, Meinhardt A, Holzinger D, Oommen PT, Hinze T, Hebart H, Seeger K, Lehmberg K, Leahy TR, Claviez A, Vieth S, Schilling FH, Fuchs I, Groß M, Rieux-Laucat F, Magerus A, Speckmann C, Schwarz K, Ehl S; ALPS Study Group. Rensing-Ehl A, et al. Among authors: willenbacher w. J Allergy Clin Immunol. 2024 Jan;153(1):297-308.e12. doi: 10.1016/j.jaci.2023.11.006. Epub 2023 Nov 17. J Allergy Clin Immunol. 2024. PMID: 37979702
98 results